- Biotechs developing gene therapies for sickle cell disease are seeing a modest uptick in buying after a 60 Minutes segment last night on the preliminary success of an unnamed gene therapy. The patient who was the primary focus appeared to have completely responded and she has been pain-free from vaso-occlusive crises since receiving the one-time treatment.
- Selected tickers: bluebird bio (BLUE +4.8%), CRISPR Therapeutics (CRSP +3%), Vertex Pharmaceuticals (VRTX +1.4%), Editas Medicine (EDIT +3.8%)